Anticoagulant Shows Promise

An experimental anticoagulant shows promise in treating people with coronary artery disease. The strong results, from two Phase II clinical studies, will be presented March 9 at the American College of Cardiology's annual scientific sessions in New Orleans. The anticoagulant, called DX-9065a, prevents the formation of blood clots earlier in the coagulation process than other anticoagulants. It does this by inhibiting the action of Factor Xa, an important player in the formation of a blood clot.